Silibinin after one brain metastasis surgery for lung or breast cancer
Part of Brain & nervous system, Cancer, Lungs & breathing, Skin clinical trials.
This trial studies silibinin, a natural substance, to help prevent brain metastasis from coming back after surgery. It is for people with lung (NSCLC) or breast cancer who have exactly one small brain metastasis that is fully removed and has a specific lab marker in the brain tissue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have lung or breast cancer, and a doctor confirmed at least one brain metastasis in tissue samples
- You have only one brain metastasis, measuring no more than 3 cm across, shown on MRI
- Surgery must have fully removed the metastasis, and a recent MRI (within 14 days) confirms this
- Your removed brain-tumor tissue must show the STAT3 signal in certain brain cells called reactive astrocytes
- You must be able to recover from surgery (no ongoing wound issues or serious post-op infection) before joining
- Your blood counts and organs (kidneys, liver, heart) must be in acceptable range, and you must be able to have MRI with contrast
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, NBQ72S, for people with breast cancer that has spread to the lining of the brain or spinal cord (leptomeningeal metastasis). It aims to see if the drug is safe and helpful for these patients.
This study tests a combination of a new immunotherapy drug (ivonescimab), standard chemotherapy, and focused radiation (stereotactic radiosurgery) for non-small cell lung cancer that has spread to the brain. The goal is to see if this combination can shrink tumors in both the lungs and brain.
This trial tests whether using focused ultrasound to temporarily open the brain’s blood barrier—plus standard immune therapy—can better treat non-small cell lung cancer (NSCLC) that has spread to the brain. It aims to help medicines reach the brain tumor spots more effectively, while still using the usual lung cancer treatment.
This trial tests a combination of focused radiation (stereotactic radiosurgery) and an oral targeted therapy called anlotinib for people with non-small cell lung cancer that has spread to the brain. It may offer a way to control brain metastases without more invasive procedures.
This trial tests whether some people with brain metastases from solid tumors can safely skip radiation if their cancer drugs (like targeted therapy, immunotherapy, or certain chemotherapies) shrink the brain tumors. You will get MRI scans to see if the drugs are working.
This trial tests whether adding silibinin (a plant-based supplement) to standard chemotherapy drugs (daunorubicin or idarubicin) helps treat newly diagnosed acute myeloid leukemia (AML), a serious blood cancer. The goal is to see if this combination is more effective and safer than chemotherapy alone.
Hear when a new Brain Metastases, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.